📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial. (2021)

First Author: Attard G

Attributed to: Evaluating new healthcare technologies in cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.eururo.2021.06.023

PubMed Identifier: 34274134

Publication URI: http://europepmc.org/abstract/MED/34274134

Type: Journal Article/Review

Volume: 80

Parent Publication: European urology

Issue: 4

ISSN: 0302-2838